Vaughan Nelson Investment Management L.P. Has $1.87 Million Stock Holdings in Johnson & Johnson $JNJ

Vaughan Nelson Investment Management L.P. lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 54.2% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 9,015 shares of the company’s stock after selling 10,675 shares during the quarter. Vaughan Nelson Investment Management L.P.’s holdings in Johnson & Johnson were worth $1,866,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of JNJ. Abich Financial Wealth Management LLC bought a new position in Johnson & Johnson during the third quarter worth about $26,000. Evolution Wealth Management Inc. bought a new stake in shares of Johnson & Johnson in the second quarter worth about $27,000. Clayton Financial Group LLC acquired a new stake in shares of Johnson & Johnson during the third quarter worth about $28,000. Semmax Financial Advisors Inc. increased its stake in Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after purchasing an additional 72 shares in the last quarter. Finally, Turning Point Benefit Group Inc. acquired a new stake in shares of Johnson & Johnson during the third quarter worth $41,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $244.20 on Thursday. The stock’s 50-day simple moving average is $238.92 and its 200 day simple moving average is $212.08. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $251.71. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. The company has a market cap of $588.19 billion, a P/E ratio of 22.10, a P/E/G ratio of 2.42 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The business had revenue of $24.28 billion for the quarter. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.1%. The ex-dividend date was Tuesday, February 24th. Johnson & Johnson’s payout ratio is 47.06%.

Insider Buying and Selling

In other news, EVP Vanessa Broadhurst sold 6,197 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the sale, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Timothy Schmid sold 1,322 shares of the firm’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the transaction, the executive vice president owned 25,447 shares in the company, valued at $6,251,310.02. The trade was a 4.94% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 30,142 shares of company stock worth $7,360,528 in the last three months. 0.16% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Morgan Stanley set a $253.00 target price on Johnson & Johnson in a report on Wednesday, March 18th. BMO Capital Markets reiterated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. HSBC lifted their target price on Johnson & Johnson from $265.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Wall Street Zen cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Finally, Royal Bank Of Canada reiterated an “outperform” rating and issued a $255.00 price objective on shares of Johnson & Johnson in a report on Monday. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average target price of $236.91.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Fool highlights JNJ’s resilience in market sell‑offs and its reliable dividend, noting a strong 2025 execution with 51 drug approvals and 15 med‑tech launches — a clear positive for revenue visibility and defensive appeal. This Healthcare Stock Barely Flinches During Market Sell-Offs
• Positive Sentiment: Royalty Pharma agreed to a $500M R&D collaboration with J&J to support an experimental antibody for autoimmune disease — a near‑term financing/partnering win that validates parts of JNJ’s biotech pipeline. Royalty Pharma, Johnson & Johnson Strike $500M Autoimmune Drug Deal
• Positive Sentiment: Royal Bank of Canada reaffirmed its “Outperform” rating, giving institutional validation that can support investor demand. Royal Bank Of Canada Reaffirms “Outperform” Rating for Johnson & Johnson (NYSE:JNJ)
• Positive Sentiment: Macro/sector commentary (Fool, 247wallst) is casting JNJ as a defensive, dividend‑paying name that holds up in stagflation or volatile markets — supporting its premium multiple and safe‑haven flows. Stagflation Fears Are Back: These 3 Stocks Can Help You Ride Out the Storm
• Neutral Sentiment: Zacks and Yahoo pieces note that JNJ is a “trending” stock with a history of earnings beats — attention that can boost volume but doesn’t by itself change fundamentals. Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Broad market moves (geopolitics and oil) and media coverage of JNJ’s rebound and ongoing litigation create background noise — they affect volatility but not immediate fundamentals. Dow Jones Futures Rise, Oil Prices Fall Below $100; Trump To Speak To Nation On Iran War
• Negative Sentiment: Bridgewater’s Ray Dalio trimmed his JNJ position — a minor red flag given his long‑term ownership, but reports indicate it was a small reduction rather than a large exit. Johnson & Johnson (JNJ): Billionaire Ray Dalio Trims Position

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.